On November 27, Acelyrin Issued Press Release That Included References To Two Clinical Trials On Its Investigational Product, For Which Fortrea Served As CRO. Fortrea Objects To The Implications That Fortrea's Study Conduct Impacted The Trial Outcomes-8K
Portfolio Pulse from Benzinga Newsdesk
Acelyrin issued a press release on November 27 that referenced two clinical trials for its investigational product, with Fortrea acting as the CRO. Fortrea has objected to any implications that its conduct influenced the trial outcomes, as stated in an 8K filing.
November 29, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Fortrea, the CRO for Acelyrin's clinical trials, has objected to implications in a press release that its conduct affected trial outcomes.
Fortrea's objection to the implications made by Acelyrin could lead to legal scrutiny or reputational damage, potentially affecting investor confidence and the stock price negatively in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80